Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M–Positive NSCLC

Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M–Positive NSCLC

Introduction: Recent advances in the detection of genomic DNA from plasma samples allow us to follow tumor DNA shedding in plasma during systemic treatment. Osimertinib is the standard of care for patients with NSCLC with acquired EGFR T790M mutations. We assessed changes in serial plasma cell-free...

Full description

Bibliographic Details
Main Authors: Bin-Chi Liao, MD, Wei-Hsun Hsu, MD, Jih-Hsiang Lee, MD, Ching-Yao Yang, MD, PhD, Tzu-Hsiu Tsai, MD, PhD, Wei-Yu Liao, MD, PhD, Chao-Chi Ho, MD, PhD, Chia-Chi Lin, MD, PhD, Jin-Yuan Shih, MD, PhD, Chong-Jen Yu, MD, PhD, Ross A. Soo, M.B.B.S., James Chih-Hsin Yang, MD, PhD
Format: Article
Language:English
Published: Elsevier 2021-01-01
Series:JTO Clinical and Research Reports
Subjects:
Non–small cell lung cancer
EGFR mutations
ctDNA
Osimertinib
Outcome prediction
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364320301454

Internet

http://www.sciencedirect.com/science/article/pii/S2666364320301454

Similar Items